|
Animal studies
| | | | | |
|
Schizophrenia
|
200 and 400 mg/kg
|
In vivo
|
reduced mean episodes of rearing and mean climbing scores
|
2017
|
[119]
|
|
MK-801-induced schizophrenia
|
40 mg/kg or 80 mg/kg
|
In vivo
|
Increased expression of SIRT1 and BDNF, decreased oxidative stress
|
2020
|
[134]
|
|
Schizophrenia
|
20 mg/kg
|
In vivo
|
Decreased VCMs
|
2017
|
[135]
|
|
MIA-induced schizophrenia
|
40 mg/kg
|
In vivo
|
Ameliorated hyperlocomotion and social behavior
|
2020
|
[136]
|
|
Human studies
| | | | | |
|
Schizophrenia
|
200 mg/day
|
Human
|
No significant changes
|
2016
|
[137]
|
|
Schizophrenia
|
200 mg/day
|
Human
|
No significant changes
|
2016
|
[138]
|
